Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
5.12
+0.03 (0.59%)
Apr 9, 2026, 1:22 PM EDT - Market open
Larimar Therapeutics Market Cap
Larimar Therapeutics has a market cap or net worth of $531.88 million as of April 9, 2026. Its market cap has increased by 264.34% in one year.
Market Cap
531.88M
Enterprise Value
393.90M
1-Year Change
264.34%
Ranking
Category
Stock Price
$5.12
Market Cap Chart
Since May 29, 2020, Larimar Therapeutics's market cap has increased from $113.38M to $531.88M, an increase of 369.11%. That is a compound annual growth rate of 30.16%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 8, 2026 | 528.76M | 62.15% |
| Dec 31, 2025 | 326.10M | 32.06% |
| Dec 31, 2024 | 246.93M | 23.61% |
| Dec 29, 2023 | 199.77M | 11.79% |
| Dec 30, 2022 | 178.70M | -6.49% |
| Dec 31, 2021 | 191.10M | -41.88% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| May 29, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Rigel Pharmaceuticals | 549.21M |
| Aclaris Therapeutics | 549.03M |
| Valneva SE | 546.53M |
| Zura Bio | 540.82M |
| Upstream Bio | 535.49M |
| Lyell Immunopharma | 534.45M |
| Fulcrum Therapeutics | 526.14M |
| 4D Molecular Therapeutics | 515.62M |